Volume 24, Number 8—August 2018
Research
Enhanced Surveillance for Coccidioidomycosis, 14 US States, 2016
Table 1
Characteristic | Value |
---|---|
Total no. patients |
186 (100) |
Demographics | |
Sex | |
M | 109 (59) |
F | 77 (41) |
Median age, y (range), n = 185 | 65 (7–91) |
Race, n = 170 | |
White | 151 (89) |
Black/African American | 9 (5) |
Asian | 1 (0.6) |
American Indian or Alaska Native | 3 (2) |
Other | 6 (4) |
Hispanic or Latino, n = 175 | 19 (11) |
Health insurance coverage, n = 158 | 148 (94) |
Some college education or higher, n = 137 | 91 (66) |
Annual household income >$50,000, n = 104 |
56 (54) |
Underlying medical conditions | |
Smoking, n = 171 | |
Currently | 10 (6) |
In the past | 74 (43) |
None | 87 (51) |
Asthma requiring an inhaler | 20 (11) |
COPD or emphysema | 18 (10) |
Other lung disease | 13 (7) |
Diabetes | 35 (19) |
HIV/AIDS | 2 (1) |
Heart disease | 35 (19) |
Cancer | 32 (17) |
Transplant | 2 (1) |
Liver disease | 9 (5) |
Kidney disease | 9 (5) |
Other major illness | 49 (26) |
No underlying medical conditions reported | 61 (34) |
Immunosuppressed† | 36 (19) |
Immunosuppressive medications, n = 165 | 32 (19) |
History of coccidioidomycosis, n = 174 | 12 (7) |
*Values are no. (%) patients except as indicated. n values are provided for categories with <186 responses.
†Defined as HIV/AIDS, solid organ or bone marrow transplant, or immunosuppressive medication use.
Page created: July 17, 2018
Page updated: July 17, 2018
Page reviewed: July 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.